Edgar Filing: BRISTOW DUKE K - Form 4

DDIGTOW DUVE V

Form 4								
January 04, 2005						OMB APPROVAL		
UNITEDS		RITIES AND EX Shington, D.C. 20		COMMISSION	OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or	ENT OF CHAN	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES				Estimated average burden hours per		
obligations may continue. Section 17(a See Instruction 1(b).	a) of the Public U	16(a) of the Securit Jtility Holding Con nvestment Compan	npany Act	of 1935 or Sectio				
(Print or Type Responses)								
1. Name and Address of Reporting P BRISTOW DUKE K	Symbol	er Name and Ticker or A PHARMACEUT	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
	INC [A	ARNA]	(Check an applicable)					
(Last) (First) (M C/O ARENA PHARMACEUTICALS, INC NANCY RIDGE DRIVE	(Month/ 12/31/2	of Earliest Transaction Day/Year) 2004		XDirector Officer (give below)		6 Owner er (specify		
(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
SAN DIEGO, CA 92121					More than One R			
(City) (State) (A	(Zip) Tab	ole I - Non-Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned		
(Instr. 3)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securiti TransactionAcquired Code Disposed (Instr. 8) (Instr. 3, 4) Code V Amount	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report on a separate line f	for each class of sec			or indirectly.				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: BRISTOW DUKE K - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number out Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerci Expiration Dat (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 6.7	12/31/2004		A	2,239	12/31/2004	12/31/2014	Common Stock	2,239

Reporting Owners

Reporting Owner Name / Address		Relationships					
reporting of the Funct Functions	Director	10% Owner	Officer	Other			
BRISTOW DUKE K C/O ARENA PHARMACEUTICALS, INC 6166 NANCY RIDGE DRIVE SAN DIEGO, CA 92121	X X						
Signatures							
Adam S. Chinnock, as Attorney-in-Fact	01/03/2005	5					
<u>**</u> Signature of Reporting Person	Date						
Evaluation of Deenene.							

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.